WO1999059561A3 - Resveratrol inhibition of myeloperoxidase - Google Patents

Resveratrol inhibition of myeloperoxidase Download PDF

Info

Publication number
WO1999059561A3
WO1999059561A3 PCT/US1999/010969 US9910969W WO9959561A3 WO 1999059561 A3 WO1999059561 A3 WO 1999059561A3 US 9910969 W US9910969 W US 9910969W WO 9959561 A3 WO9959561 A3 WO 9959561A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
inflammatory
resveratrol
myeloperoxidase
inhibition
Prior art date
Application number
PCT/US1999/010969
Other languages
French (fr)
Other versions
WO1999059561A2 (en
Inventor
Kenneth L Hensley
Robert A Floyd
Original Assignee
Oklahoma Med Res Found
Kenneth L Hensley
Robert A Floyd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Kenneth L Hensley, Robert A Floyd filed Critical Oklahoma Med Res Found
Priority to AU40845/99A priority Critical patent/AU4084599A/en
Publication of WO1999059561A2 publication Critical patent/WO1999059561A2/en
Publication of WO1999059561A3 publication Critical patent/WO1999059561A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Resveratrol and its derivatives are potent inhibitors of myeloperoxides, an enzyme released by neutrophils which causes tissue damage in diseases involving chronic inflammation. Such diseases include but are not limited to atherosclerosis, arthritis, Alzheimer's disease, sepsis (endotoxic shock), inflammatory skin disease (psoriasis), inflammatory gum disease (gingivitis), and inflammatory bowel disease.
PCT/US1999/010969 1998-05-18 1999-05-18 Resveratrol inhibition of myeloperoxidase WO1999059561A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU40845/99A AU4084599A (en) 1998-05-18 1999-05-18 Resveratrol inhibition of myeloperoxidase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8582198P 1998-05-18 1998-05-18
US60/085,821980518 1998-05-18

Publications (2)

Publication Number Publication Date
WO1999059561A2 WO1999059561A2 (en) 1999-11-25
WO1999059561A3 true WO1999059561A3 (en) 2000-04-27

Family

ID=22194174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010969 WO1999059561A2 (en) 1998-05-18 1999-05-18 Resveratrol inhibition of myeloperoxidase

Country Status (2)

Country Link
AU (1) AU4084599A (en)
WO (1) WO1999059561A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868047B2 (en) 1999-12-06 2011-01-11 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184248B1 (en) 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US20050245612A1 (en) * 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
IT1302365B1 (en) 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa USE OF CARNITINE AND RESVERATROL TO PRODUCE A COMPOSITION FOR THE PREVENTION OR THERAPEUTIC TREATMENT OF BRAIN ALTERATIONS
US6716883B1 (en) 1998-12-24 2004-04-06 1333366 Ontario Inc. Composition useful to treat periodontal disease
WO2000038620A2 (en) * 1998-12-24 2000-07-06 1333366 Ontario Inc. A composition useful to treat periodontal disease
PE20010540A1 (en) * 1999-07-30 2001-05-15 Procter & Gamble COMPOSITION OF STYLBENE PHYTOALEXINS USEFUL FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES
CA2393297C (en) * 1999-12-06 2010-10-05 Welichem Biotech Inc. Polyhydroxystilbenes as antipsoriatic agents and protein kinase inhibitors
IT1318425B1 (en) * 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro USE OF RESVERATROL FOR THE TREATMENT OF DESQUAMATIVE ECZEMA, ACNE AND PSORIASIS.
GB2362101A (en) * 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
WO2002038141A2 (en) * 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Compositions and methods for treatment of mild cognitive impairment
FR2816843B1 (en) * 2000-11-23 2006-10-27 Actichem INHIBITORS OF ENZYME 5 ALPHA-REDUCTASE
CN101810600B (en) * 2001-11-02 2012-11-21 加州大学校务委员会 Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
WO2003077900A1 (en) 2002-03-14 2003-09-25 Prevention, L.L.C. A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
JP5335192B2 (en) 2003-05-27 2013-11-06 ディーエスエム アイピー アセッツ ビー．ブイ． Novel dietary supplement composition and use thereof
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
CN102309573B (en) * 2003-09-12 2013-11-20 捷通国际有限公司 Cytokine modulators and related method of use
CA2548671C (en) 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006076681A2 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
FR2882502B1 (en) * 2005-02-25 2007-04-20 Claude Bonne FOOD SUPPLEMENTS FOR PATIENTS WITH PSORIASIS
WO2006102407A2 (en) 2005-03-23 2006-09-28 Children's Medical Center Corporation Orthotic device for preventing and/or correcting deformational posterior plagiocephaly
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2008006582A1 (en) * 2006-07-14 2008-01-17 Dsm Ip Assets B.V. Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases
US20120016037A1 (en) * 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
US20100240767A1 (en) * 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
US8883218B2 (en) 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
US9044491B2 (en) * 2010-12-28 2015-06-02 The Board Of Trustees Of The University Of Arkansas Method for improving blood flow using stilbenoid derivatives
US9095598B2 (en) * 2010-12-28 2015-08-04 The Board Of Trustees Of The University Of Arkansas Stilbenoid derivatives and their uses
AP2014007621A0 (en) 2011-11-11 2014-05-31 Pfizer 2-Thiopyrimidinones
CN102816090A (en) * 2012-09-10 2012-12-12 四川大学 Carbamate compounds, preparation method and application thereof
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
US10667627B2 (en) 2015-05-05 2020-06-02 Children's Medical Center Corporation Devices and methods for supporting and containing premature babies and small-for-age infants
TN2017000461A1 (en) 2015-05-05 2019-04-12 Pfizer 2-thiopyrimidinones
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
HUE059066T2 (en) 2015-05-21 2022-10-28 Dermavant Sciences GmbH Topical pharmaceutical compositions
JP6912664B2 (en) 2017-11-10 2021-08-04 ダーマヴァント サイエンシーズ ゲーエムベーハー Process for preparing tapinarov
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6160609A (en) * 1984-08-31 1986-03-28 Green Cross Corp:The Lipoxygenase inhibitor
JPS61171427A (en) * 1985-01-24 1986-08-02 Osaka Chem Lab Substance for preventing thrombosis or the like
EP0448253A2 (en) * 1990-03-19 1991-09-25 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
JPH04159280A (en) * 1990-10-24 1992-06-02 Tsumura & Co 5-lipoxygenase inhibitor containing hydroxystilbene-based compound as active ingredient
EP0664125A1 (en) * 1993-12-21 1995-07-26 Eli Lilly And Company Inhibition of myeloperoxidase activity
EP0773020A2 (en) * 1995-10-17 1997-05-14 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Pharmaceutical compositions containing L-carnitine or derivatives thereof in combination with resveratrol or derivatives thereof, for the prophylaxis and treatment of cardiovascular disorders, peripheral vascular diseases and peripheral diabetic neuropathy

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6160609A (en) * 1984-08-31 1986-03-28 Green Cross Corp:The Lipoxygenase inhibitor
JPS61171427A (en) * 1985-01-24 1986-08-02 Osaka Chem Lab Substance for preventing thrombosis or the like
EP0448253A2 (en) * 1990-03-19 1991-09-25 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
JPH04159280A (en) * 1990-10-24 1992-06-02 Tsumura & Co 5-lipoxygenase inhibitor containing hydroxystilbene-based compound as active ingredient
EP0664125A1 (en) * 1993-12-21 1995-07-26 Eli Lilly And Company Inhibition of myeloperoxidase activity
EP0773020A2 (en) * 1995-10-17 1997-05-14 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Pharmaceutical compositions containing L-carnitine or derivatives thereof in combination with resveratrol or derivatives thereof, for the prophylaxis and treatment of cardiovascular disorders, peripheral vascular diseases and peripheral diabetic neuropathy

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BOYD B.L.: "Multidisciplinary meeting on inflammation and related diseases.", DRUG NEWS AND PERSPECTIVES, (1997) 10/4 (254-256)., XP000856551 *
JANG M ET AL: "Cancer chemopreventive activity of resveratrol.", DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, (1999) 25 (2-3) 65-77., XP000856543 *
JANG M ET AL: "Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate- induced oxidative events and gene expression in mouse skin.", CANCER LETTERS, (1998 DEC 11) 134 (1) 81-9., XP000856544 *
MEISHIANG ET AL.: "Cancer Chemopreventive Activity of Resveratrol, a natural product Derived from grapes", SCIENCE, vol. 275, 1997, pages 218- - 220, XP002124508 *
PATENT ABSTRACTS OF JAPAN vol. 010, no. 226 (C - 364) 7 August 1986 (1986-08-07) *
PATENT ABSTRACTS OF JAPAN vol. 010, no. 377 (C - 392) 16 December 1986 (1986-12-16) *
PATENT ABSTRACTS OF JAPAN vol. 016, no. 455 (C - 0987) 22 September 1992 (1992-09-22) *
SMITH R J ET AL: "Effects of an anion channel blocker, 4, 4'-diisothiocyano-2,2'- disulfonic acid stilbene (DIDS), on human neutrophil function.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1984 MAY 16) 120 (3) 964-72., XP000856591 *
SOLEAS, GEORGE J. ET AL: "Resveratrol: a molecule whose time has come? and gone?", CLIN. BIOCHEM. (1997), 30(2), 91-113, XP000856542 *
SUN, ALBERT Y. ET AL: "The protective action of resveratrol on apoptotic cell death induced by oxidized lipoproteins", BIOL. OXID. ANTIOXID. (1998), 210-222. EDITOR(S): PACKER, LESTER;ONG, AUGUSTINE S. H. PUBLISHER: AOCS PRESS, CHAMPAIGN, ILL., XP000856685 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868047B2 (en) 1999-12-06 2011-01-11 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues

Also Published As

Publication number Publication date
WO1999059561A2 (en) 1999-11-25
AU4084599A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
WO1999059561A3 (en) Resveratrol inhibition of myeloperoxidase
BG105109A (en) Cell adhesion-inhibiting anti-inflammatory compounds
LU91076I2 (en) Tulathromycin and its pharmaceutically acceptable salts (draxxin).
DE69824183T2 (en) N-ALKANOYLPHENYLALANINDERIVATE
MX9606546A (en) INHIBITORS OF INTERLEUKIN-1'beta' CONVERTING ENZYME.
SE9504661D0 (en) New compounds
ID23496A (en) PLANT EXTRACT TO TREAT IMPROVEMENT OF BONE RESORTS
TR200101124T2 (en) N- (2-aryl-propionyl) -sulphonamides and pharmaceutical preparations containing them.
BG103518A (en) 2-(purin-9-yl)tetrahydrofuran-3,4-diol derivatives
EP1034164A4 (en) Substituted beta-alanine derivatives as cell adhesion inhibitors
NO20006115D0 (en) New 3-aryl-2-hydroxypropionic acid derivative (I)
TR200002446T2 (en) Inhibitors of phospholipase enzymes
BR9916746A (en) Antiinflammatory compounds that inhibit cell adhesion
ATE263751T1 (en) OLEAMIDE HYDROLASE INHIBITORS
ES2189768T3 (en) REGIONAL ELEMENTARY SYNTHESIS OF RAPAMYCIN DERIVATIVES.
AU2003274052A1 (en) Use of cellulose microbeads to make the skin matt
BR0109780A (en) Stabilized ascorbic acid solutions; use of them; process for obtaining them and formulations comprising the same
IL129026A0 (en) Sulfonamide interleukin-1beta converting enzyme inhibitors
EA200000204A1 (en) Pyrrolopyrlonone derivatives as ELASTASIS INHIBITORS NEUTROPHILS
IS6363A (en) Ox (adi) azolyl hydroxamic acids useful as procollagen C proteinase inhibitors
ATE516027T1 (en) ORAZAMID OROTAT TO PREVENT LIVER DAMAGE
PL333112A1 (en) Substitute derivatives of 4-biphenyl-4-hydroxybutyric acid as inhibitors of matrix metaloproteases
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
IL129124A0 (en) Sulfonamide substituted aspartic acid interleukin -1beta converting enzyme inhibitors
RU2001120358A (en) APPLICATION OF SODIUM-HYDROGEN-ANTIPORTER INHIBITORS FOR PRODUCTION OF MEDICINE FOR INHIBITION OF AGE-DYSFUNCTIONED ORGANIZED BODIES DUE TO AGE OF DISEASES AND FOR LENGTH LENGTH

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE